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y. Methods: A literature review was conducted in order to address two ques-
tions: What is oxidative stress and how does oxidative stress come about? 
 Results: Oxidative stress is caused by an imbalance between the pro-
duction of reactive oxygen and a biological system’s ability to readily 
detoxify the reactive intermediates or easily repair the resulting dam-
age. Disturbances in a cells normal redox state can cause toxic effects 
through the production of peroxides and free radicals that damage all 
components of the cell, including proteins, lipids, and DNA. 
 Conclusions : Interpretation of molecular investigations in schizophrenia 
might benefi t from considering whether the results obtained could be the 
cause or consequence of oxidative stress. Causal fi ndings could suggest 
more specifi c treatments for schizophrenia and allied disorders. 
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 Background: Evidence suggests that oxidative damage exists in the brains 
of patients with schizophrenia, however, it is not yet clear how this is 
occurring. In the present study, we determined whether oxidative stress 
response markers are altered in the DLPFC of the human prefrontal cortex 
and whether changes in glial cells, such as astrocytes and microglia, may 
be contributing towards the schizophrenia neuropathology. 
 Methods: Utilizing a cohort of n  37/37 controls/schizophrenics from 
the Sydney NSW Tissue Resource Centre, we assessed gene expression 
changes by Taqman quantitative real-time PCR and protein expression 
alterations by western blotting. 
 Results and Conclusions: No signifi cant changes were observed in mRNA 
expression of several biochemical markers of the oxidative stress response 
including SOD1, GPX3, and apoD between control and schizophrenics. 
Interestingly, age-dependent upregulation of apoD was not found in schizo-
phrenia. We found no signifi cant changes in GFAP expression compared to 
controls, moreover, age-dependent regulation of GFAP was not found. Inter-
estingly, we found increased expression of a marker of total (Glut5) but not 
activated microglia (HLADR) protein. This suggests that cellular response 
to oxidative stress in the DLPFC may be altered in schizophrenia. Astrocytes 
responsible for neuronal support may not be responding to redox perturba-
tions as age-dependent regulation of GFAP and apoD expressions are lost 
in schizophrenia, moreover, increased expression of total microglia with no 
change in activated microglia, GPX3 and SOD1 in schizophrenia may indi-
cate a lack of free radical detoxifi cation. Thus, glial cell dysfunction in 
schizophrenia may be an underlying factor in the neuropathology. 
 SP39 - THE SPECIFICITY OF PATHOGENIC 
OXIDATIVE STRESS IN SCHIZOPHRENIA 
 Olivia Dean 1 , 2 , Michael Berk 1,2 
 
1
 Mental Health Research Institute, Victoria, Australia 
 
2
 Department of Clinical and Biomedical Sciences: Barwon Health, 
University of Melbourne, Victoria Australia  Background: The role of oxidative stress has become an important factor 
in uncovering the pathophysiology of schizophrenia. There is substantial 
evidence to suggest not only downstream changes in oxidative defenses, 
but also more global changes including alterations to mitochondrial func-
tion, neurotrophins, and polymorphisms in genes associated with primary 
antioxidants. More and more these factors are being implicated in a variety 
of psychiatric disorders, indicating that oxidative stress is not specifi c to 
schizophrenia but may be a common feature of many disorders. 
 Method: The current presentation will provide an overview of the 
commonality of oxidative stress across several psychiatric illnesses, 
demonstrating a wider view of a continuum of psychiatric illness. 
 Results: As the fi eld of oxidative biology and psychiatric illness 
expands it is becoming apparent that there are many more similarities 
in the underlying pathology of these disorders that fi rst suspected. 
 Conclusions: Based on current literature, the notion of specifi city of 
oxidative stress in schizophrenia is not supported. Changes in oxidative 
defenses are occurring in many psychiatric disorders. Further investiga-
tion of whether these changes are a consequence or a primary part of 
these disorders is required. This will not only provide a better understand-
ing of these disorders, but also lead the way to new treatment targets. 
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 Background: There is increasing evidence of impaired antioxidant 
defense systems, increased lipid peroxidation and abnormal levels of 
polyunsaturated fatty acids (PUFAs) in patients suffering from schizo-
phrenia. The synthesis of the main intracellular redox regulator and 
cellular antioxidant, glutathione (GSH), was shown to be impaired in 
schizophrenia. A GSH defi cit is associated with lipid membrane per-
oxidation during excessive oxidative stress. 
 Methods: Clinical trials were conducted with the objective of improving 
the GSH and/or the PUFAs status and of seeing the effects of such an 
improvement on the psychopathology and neurobiology of participants. 
N-Acetyl-Cysteine (NAC), a precursor of GSH and antioxidant itself, was 
administered to schizophrenia patients in Lausanne and Melbourne. An 
intervention with omega-3 PUFAs was conducted in Vienna. 
 Results: Treatment with NAC was accompanied by an amelioration of 
negative symptoms and global symptomatology and reduction of antip-
sychotic-induced akathisia. The mismatch negativity, an EEG compo-
nent refl ecting the functioning of NMDA receptors, was also improved. 
Treatment with omega-3 PUFAs reduced the risk of progression to 
psychotic disorders. 
 Conclusions : Based on the literature, mechanisms involving NMDA 
receptors function and cell membrane integrity will be proposed in an 
attempt to explain the actions of NAC and omega-3 PUFAs. The inter-
esting fi ndings will also be presented in a perspective of early intervention 
in psychosis. 
